NCT05604560
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05604560
Title A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Lei Zheng
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.